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All institutional review boards approved the study, and in-
formed consent is obtained before study enrollment. Par-
ticipants are enrolled from a random sample of the gen-
eral population at five dedicated imaging sites among 18 
recruitment centers. MR imaging facilities are equipped 
with identical 3.0-T imager technology and use uniform 
MR protocols. Imager-specific hardware and software set-
tings remained constant over the study period. On-site 
and centralized measures of image quality enable moni-
toring of completeness of the acquisitions and quality of 
each of the MR sequences. Certified radiologists read all 
MR imaging studies for presence of incidental findings ac-
cording to predefined algorithms.
Results: Over a 4-year period, six participants per day are exam-
ined at each center, totaling a final imaging cohort of ap-
proximately 30 000 participants. The MR imaging protocol 
is identical for each site and comprises a set of 12 native 
series to cover neurologic, cardiovascular, thoracoabdomi-
nal, and musculoskeletal imaging phenotypes totaling ap-
proximately 1 hour of imaging time. A dedicated analysis 
platform as part of a central imaging core incorporates a 
thin client-based integrative and modular data handling 
platform to enable multicentric off-site image reading for 
incidental findings. Scientific analysis will be pursued on a 
per-project hypothesis-driven basis.
Conclusion: Population-based whole-body MR imaging as part of the 
German National Cohort will serve to compile a compre-
hensive image repository, will provide insight into phys-
iologic variants and subclinical disease burden, and has 
the potential to enable identification of novel imaging bio-
markers of risk.
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Implication for Patient Care
 n Large prospective cohort studies 
are required to determine the 
prognostic value of techniques 
such as whole-body MR imaging 
in the identification of partici-
pants in the general population 
who are at increased risk for 
overt disease development.
Advances in Knowledge
 n The MR study of the German Na-
tional Cohort will enroll approxi-
mately 30 000 as ymptomatic par-
ticipants from the German general 
population at five imaging sites and 
will include a com prehensive whole-
body MR imag ing protocol of ap-
proximately 1 hour.
 n Standardized procedures of 
quality control and quality assur-
ance, as well as algorithms for 
the management of incidental 
findings and basic integrative and 
modular data-handling strategies, 
have been incorporated.
 n The highly stabilized set-up of the 
German National Cohort MR 
imaging study will be used to 
understand the natural history of 
a broad set of diseases and to 
potentially identify novel imaging 
biomarkers of risk.
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The implementation of advanced imaging techniques in large cohort studies has been an increasingly 
used approach in epidemiologic research 
(1). Traditionally, longitudinal studies 
have relied on the clinical assessment 
of established and novel risk factors at 
baseline and their relation to the inci-
dence of clinically overt events, such as 
stroke, myocardial infarction, or death 
over the follow-up period (2). While 
this design has served us well in the 
identification of many now-established 
risk factors for various disease states, 
its power is limited to the number of 
overt events in the source population. 
Over the past two decades, imaging 
has increasingly been implemented in 
population-based cohorts to obtain in-
formation on the presence and extent 
of subclinical disease burden, allowing 
for a more comprehensive assessment 
of development of disease states. This 
has resulted in improved understanding 
of complex disease processes, as well 
as identification of novel imaging bio-
markers as a precursor for overt disease 
states. Prominent examples include the 
Rotterdam study (3), the Framingham 
Heart study (4), the Multi-Ethnic Study 
of Atherosclerosis (5), the Heinz Nixdorf 
MR imaging has advanced to a stage 
that allows nonionizing visualization of 
morphologic and functional processes 
without the need to administer a contrast 
agent. Its capability to perform examin-
er-independent, multiregion and whole-
body MR imaging in clinical routine is 
a recent development (14,15) with a 
potentially high value for comprehensive 
phenotyping in a population-based im-
aging setting. Technical improvements, 
such as the introduction of multichan-
nel radiofrequency receiver architecture 
(16), parallel acquisition techniques 
(17–19), continuous table movement 
techniques, and pulse sequence devel-
opments (20) enable the examination of 
different organ systems in a whole-body 
approach within a reasonable imaging 
time (21,22). Also, unenhanced MR 
imaging–based angiography has been 
shown to be an alternative modality that 
yields images of high quality in partici-
pants who are not amenable to contrast 
material administration (23,24). As a 
consequence, these novel developments 
Recall study (6), the Study of Health in 
Pomerania (7), and the Atherosclerosis 
Risk in Communities study (8). Exam-
ples of novel imaging-based markers of 
risk include coronary calcification with 
computed tomography (CT) (9,10), as-
sessment of left ventricular function/
fibrosis or hepatic steatosis with mag-
netic resonance (MR) imaging (11,12), 
and evaluation of intimamedia thickness 
with ultrasonography (13).
There are substantial advantages of 
using imaging-based measures of subclin-
ical disease to identify the disease prior 
to clinical signs and symptoms in studies 
on disease etiology. Early detection of 
subclinical disease may enable more effi-
cient and effective initiation of preventive 
measures and treatment interventions at 
early stages as compared with later stag-
es of disease. Also, cross-sectional and 
case-control analyses may be less suscep-
tible to recall bias or bias due to reverse 
causation related to treatment if the out-
come is defined by subclinical disease as 
detected with imaging instead of with 
clinical endpoints (5). Finally, imaging 
biomarkers, with their potentially contin-
uous scale of most subclinical measures 
(continuous measures of volume, diame-
ter, and extent), yield significantly higher 
statistical power compared with dichoto-
mous discrete measures of clinical disease 
(presence or absence) (1). Besides being 
used to assess subclinical disease burden, 
advanced imaging modalities may enable 
identification of a large set of normal var-
iation and variants, which may be of par-
ticular interest to the scientific commu-
nity and may signify susceptibility for a 
certain disease development. In case any 
risk factor role can be detected, one may 
hypothesize that it may serve as a tool 
to identify subjects who may benefit from 
primary prevention strategies.
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enable comprehensive quantitative as-
sessment of adipose tissue distribution; 
characterization of brain and cardiac 
function and morphology, as well as 
characterization of thoracic and abdomi-
nal organs; and quantification of changes 
in the musculoskeletal system.
The German National Cohort is de-
signed to address research questions 
concerning a wide variety of possible 
causes and mechanisms for the devel-
opment of frequent chronic diseases 
(25). The major objective of the Ger-
man National Cohort is to identify risk 
factors and protective factors for popu-
lation-relevant diseases and age-related 
declines in health to improve our un-
derstanding of disease etiology and to 
provide new information that can even-
tually be translated to primary preven-
tion measures. The main diseases of in-
terest include cardiovascular diseases, 
diabetes mellitus, cancer, neurologic 
and psychiatric diseases, and respira-
tory, infectious, and musculoskeletal 
diseases. Special research emphasis will 
be given to the association and interac-
tions between biomarkers, subclinical 
disorders, and their predictive value for 
future clinical manifestation of disease. 
Given these general broad objectives of 
the German National Cohort, whole-
body MR imaging may be a unique 
modality with which to serve these ob-
jectives by enabling assessment of sub-
clinical disease and normal variants of 
the different organ systems within one 
comprehensive examination with high 
spatial and temporal resolution. How-
ever, while the scientific potential of im-
plementing MR imaging in large cohort 
studies is substantial, there are numer-
ous ethical and procedural challenges 
associated with a multicenter study on 
whole-body imaging in predominantly 
asymptomatic participants, especially 
in the case of unintended detection of 
clinically relevant incidental findings. 
To be qualified to serve as a scientific 
reference standard, it is essential to 
establish high-quality and standardized 
MR imaging data across different im-
aging sites over a few years of baseline 
data collection. At the same time, it 
has to be ensured that the applied sci-
entific procedures do not compromise 
the interests and the human dignity of 
research participants with detectable 
incidental findings (26,27). Also, the 
acquisition, storage, and processing of 
large amounts of imaging data acquired 
at different sites requires established 
workflow and data management struc-
tures. In sum, all of the described chal-
lenges in these comprehensive acquisi-
tions warrant dedicated resources and 
management algorithms.
In the present report, we describe 
the rationale and design of the MR Im-
aging Study of the German National Co-
hort. Also, we detail the developed and 
implemented procedures with respect 
to image quality assurance, data man-
agement, study logistics, training, and 
management of incidental findings.
National Cohort Description
Study Objectives
The primary objective of this research 
effort is to establish a comprehensive 
morphologic and functional imaging 
repository; this will be achieved by 
implementing whole-body MR imaging 
in a large subset of the participants of 
the German National Cohort.
The imaging repository serves as 
a reference for the following research 
aims of the study: (a) to determine the 
predictive value of findings on whole-
body MR images for the incidence of 
chronic diseases over the follow-up pe-
riod, (b) to determine pathways for the 
prevalence of subclinical disease states 
by studying associations with similarly 
obtained biologic and socioeconomic 
markers at baseline, (c) to perform 
cross-section assessment of the preva-
lence of subclinical disease states and 
normal variants in the general popula-
tion, and (d) to develop methods that 
are suitable for application in future 
screening and intervention studies with 
which to characterize risk factors among 
asymptomatic persons.
General Design of the German National 
Cohort
The German National Cohort is a joint 
interdisciplinary endeavor by scientists 
from the Helmholtz Association, from 
universities, and from other German 
research institutions (25). Its objec-
tive is to study the causes and iden-
tify the risk factors of major chronic 
diseases (cardiovascular diseases, 
cancer, diabetes mellitus, neurode-
generative and psychiatric diseases, 
and pulmonary, musculoskeletal and 
infectious diseases) and to identify 
the subclinical stages and functional 
implications of these diseases. In 
18 study centers across Germany, a 
representative sample of the general 
population will be randomly drawn 
to include a total of 200 000 male and 
female participants between 20 and 
69 years of age. In addition to inter-
views and questionnaires, the baseline 
assessment includes a series of medi-
cal examinations, such as neurocogni-
tive function tests, tooth count, blood 
pressure measurement, pulse wave 
velocity, spirometry, accelometry, 
and the collection of a diverse set of 
biomaterials, such as blood (plasma, 
serum, DNA, RNA, and red blood 
cells), saliva samples, nasal swabs, 
and feces (level I assessment, 2.5-hour 
program). In 20% of the participants, 
an intensified assessment program 
is implemented (level II assessment, 
additional 1.5 hours of examination 
time) that includes examinations such 
as 10-second electrocardiography, 
three-dimensional (3D) echocardiogra-
phy, oral glucose tolerance testing, spi-
rometry and FeNo analysis, ophthal-
mologic measurements, olfactory tests, 
and musculoskeletal examinations.
After the baseline examination, all 
participants will be invited for reas-
sessment after 4 to 5 years. The re-
assessment will obtain information 
on incident outcomes, and part of the 
level I and II examinations (described 
previously) will be performed again. In 
addition to the reassessment after 4 to 
5 years, data on incident outcomes will 
be collected more frequently via postal 
follow-up questionnaires and linkage 
to external databases (population reg-
istries, health authorities, health insur-
ance companies, etc).
Funding is ensured for recruit-
ment and reassessment and for the 
first rounds of postal follow-up (each 
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Figure 1
Figure 1: Flowchart shows general design of the MR imaging study of the German National Cohort 
(GNC).
2–3 years), which should be achieved 
within the first 10 years.
MR Imaging Study Design
No industry funding was received for 
this study. Scientific collaborations exist, 
including collaborations with industry 
partners (Siemens Healthcare, Erlangen, 
Germany). One author (T.N.) is the chief 
executive officer of MR Imaging TOOLS 
(Berlin, Germany). Another author 
(H.U.K.) is a member of the advisory 
board of Siemens Healthcare and a con-
sultant for Boheringer Ingelheim (Ingel-
heim, Germany). All other authors de-
clare that they were neither employees 
of nor consultants for the industrial 
partners; the authors had full control 
of all data and information presented in 
this publication.
As part of the baseline examination 
of the German National Cohort study, 
a subset of approximately 30 000 of the 
200 000 participants will be recruited to 
undergo whole-body MR imaging at one 
of five dedicated MR imaging centers 
(Fig 1) as an add-on to the standard ex-
amination program of the cohort (level 
I and II examinations, as described pre-
viously). These MR imaging centers are 
distributed across Germany and are lo-
cated in Augsburg (Bavaria), Berlin (Ber-
lin), Essen (North Rhine-Westphalia), 
Neubrandenburg (Mecklenburg-West 
Pomerania), and Heidelberg (Baden-
Wurttemberg) to provide maximum 
generalizability with regards to so-
ciodemographic characteristics, such 
as migration background, specific ge-
netic predispositions, et cetera (Fig 2). 
Each MR imaging center will enroll and 
examine approximately 6000 participants 
over a 4-year enrollment period, with the 
MR examination being performed within 
a maximum of 12 weeks after the general 
baseline examination in the study center.
Sample Size Considerations for the MR 
Study
For the primary objective (ie, to es-
tablish an imaging repository), ded-
icated quality assurance algorithms 
and algorithms for the management 
of incidental findings have been imple-
mented, but no dedicated sample size 
calculations have been performed (25). 
However, for the larger number of sec-
ondary aims (ie, scientific research 
questions), a total study population of 
30 000 participants will yield adequate 
statistical power to detect associations 
between common baseline MR imaging 
markers and incident outcomes (Fig 3). 
For example, in the case of highly prev-
alent subclinical disorders, such as he-
patic steatosis, for which we expect a 
prevalence of over 20% (25), possible 
associations with incident cardiometa-
bolic disorders can be detected with 
a statistical significance after a few 
hundred incident cases have been 
collected during the first years of fol-
low-up. The study is also well powered 
for disorders that are less common. 
For instance, we expect a 3%–5% 
prevalence of MR imaging findings that 
are indicative of chronic pancreatitis 
(28). Hence, associations with a min-
imally detectable odds ratio of 1.7 in 
the presence of 400–600 cases will 
be detected, corresponding to an in-
cidence of 1.3%–2.0%, as commonly 
observed in such a population (28).
All statistical analyses will be per-
formed according to Good Epi dem-
iologic Practice guidelines and will be 
reported in accordance with STROBE 
(STrengthening the Reporting of OB-
servational studies in Epidemiology) 
guidelines (29,30).
Population and Recruitment Procedure
All institutional review boards at the five 
imaging sites approved the study, and in-
formed consent is obtained before study 
enrollment. The study population is re-
cruited from a random sample of the gen-
eral population of the surrounding com-
munities at each of the study sites. The 
MR imaging recruitment procedure is 
embedded within the recruitment proce-
dure of the general cohort study. Partici-
pants in the general assessment program 
of the German National Cohort are ran-
domly invited from the general popula-
tion sampled from population registries, 
a municipal structure that mandatorily 
lists all inhabitants with residency in a 
municipal area. Inclusion criteria for the 
German National Cohort are provided in 
Table E1 (online) (25). The number of 
participants varies according to MR im-
aging study site, with 10 000 participants 
each in Essen, Berlin, and Heidelberg and 
20 000 participants each in Augsburg and 
Neubrandenburg. Additional participants 
from adjacent study centers are invited 
to take part in MR imaging at the respec-
tive study center. At each of these sites, 
participants are approached for partici-
pation and are included if they consent to 
the MR imaging procedure and if no MR 
imaging exclusion criteria are present.
At each study site, approximately 
6000 participants in the general cohort 
210 radiology.rsna.org n Radiology: Volume 277: Number 1—October 2015
SPECIAL REPORT: MR Imaging in the German National Cohort Bamberg et al
Figure 2
Figure 2: Map of Germany shows the distribution of German National Cohort study centers and MR imaging centers.
will be included in the MR imaging ex-
amination. Participants not primarily 
assigned to level II will undergo these 
MR imaging examinations in addition to 
their level I examinations. Inclusion and 
exclusion criteria for the MR imaging 
study are listed in Table E1 (online).
Protection of Participants’ Privacy and 
Access to Research Data
With respect to data safety, we imple-
mented a central data management 
system that complies with relevant leg-
islation. This includes a strict separation 
between personal data and all other in-
formation (eg, images and biomaterials 
collected from participants). All study 
variables are deidentified and kept in a 
central study database. For data linkage, 
an independent trust center has been 
established, which exclusively holds all 
identifying information. The trust center 
links follow-up information to the individ-
ual participants and replaces identifying 
variables with pseudonyms before they 
are included in the main study database.
The German National Cohort con-
sortium is the legal owner of all data and 
biomaterials and will retain overall con-
trol of all access to the data and samples. 
The consortium strongly encourages re-
searchers to use this scientific resource. 
Like all other data and biomaterials col-
lected for the German National Cohort, 
the scientific use of MR imaging findings 
and images is dependent on an applica-
tion approved by the use and access 
committee of the German National Co-
hort. Access to the deidentified data 
will be provided to the applicants via 
a transfer center as part of a planed 
analysis platform.
Cohort Surveillance and Follow-up for 
Events
Standard follow-up of the study popula-
tion will be conducted within the main 
framework of the German National Co-
hort (25). This will include active fol-
low-up via postal questionnaires every 
2–3 years, supplemented with passive 
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Figure 3
Figure 3: Power calculations. Graphs indicate the minimal detectable risks (a= 5%; statistical power, 
80%) given a defined baseline prevalence of the exposure, number of incident cases (x-axis), and strength of 
associations (y-axis). Graphs indicate that the study size will be large enough to investigate, with high-power 
associations between common conditions (prevalence of 20% for hepatic steatosis or prostate hyperplasia, 
prevalence of 10% for left ventricular hypertrophy) and less common diseases (prevalence of 5% for cerebral 
microbleeds, prevalence of 2.5% for chronic pancreatitis) and incident outcomes. Over a 10-year follow-up 
period, we expect 2000 incident cancer cases, 5000 cases with incident cardiometabolic diseases, and 
2500 deaths from all causes.
follow-up procedures. The latter will in-
clude contacting the participant’s perti-
nent physician or physicians, hospitals 
at which they were treated, or both to 
collect further information on nonfatal 
or fatal diseases. Linkage between the 
German National Cohort and health in-
surance data and cancer registries will 
serve as additional health information 
resources. Information on vital status is 
collected annually from population regis-
tries. In case of death, health authorities 
are asked to provide death certificates. 
Also, German National Cohort data will 
be linked to the planned centralized 
German mortality registry.
Epidemiologic MR Imaging
General Consideration for Using MR 
Imaging
Population-based imaging requires a 
robust and comfortable modality that 
can be applied to a large number of 
consecutive study participants without 
major deviation, interruption, or exam-
ination cancellation. Such an imaging 
modality needs to be extremely safe 
because even very rare side effects and 
adverse events may occur due to the 
large sample size. The selected imaging 
modality should not alter the natural 
development of disease or potentially 
increase the risk for study end points 
(eg, radiation administration using CT 
and development of cancer). Also, a 
feasible population-based imaging mo-
dality should be able to include a large 
portion of the body and provide high 
spatial resolution to assess the variety 
of subtle pathologic changes of subclin-
ical disease burden with respect to the 
different organ systems.
Advanced, native MR imaging tech-
nology combines most of these aspects, 
although known contraindications may 
limit the target population and intro-
duce selection bias. While this bias 
needs to be measured prospectively, it 
can be assumed that a dedicated whole-
body MR imaging protocol provides 
the most prolific means to assess sub-
clinical disease and normal variants of 
the different organ systems within one 
comprehensive examination.
MR Imaging Examination and 
Components
Across all imaging centers, MR imag-
ing will be performed by using identical 
3.0-T MR technology with a 70-cm bore 
(Magnetom Skyra; Siemens Healthcare, 
Erlangen, Germany). Despite being 
more expensive and associated with a 
higher likelihood of artifacts, a mag-
netic field strength of 3.0 T was selected 
to leverage the improved signal-to-noise 
ratio, enhanced spatial resolution, par-
allel imaging techniques, and predicted 
future MR imaging standard in a clin-
ical environment. Examination time 
is restricted to approximately 1 hour 
to increase participant compliance. It 
will be ensured that MR hardware and 
software will remain constant over the 
study period for reasons of data con-
sistency and reproducibility, with the 
exception of safety-relevant updates 
and upgrades, which will be provided 
by the MR vendor. Each MR imaging 
site will be connected with the central 
MR imaging core to assure high proto-
col adherence and constant high image 
quality. The MR examination protocol 
comprises four dedicated components 
of approximately 15 minutes of exami-
nation time each, covering (a) cerebral 
morphology and function, (b) cardi-
vascular morphology and function, (c) 
body adipose tissue distribution, tho-
racoabdominal organ morphology and 
composition, and (d) musculoskeletal 
spinal and hip morphology (Table). 
Because of the very small but present 
risk of allergic reactions to the contrast 
agent, necessary assessment of kidney 
function, and complexity of the intra-
venous line positioning in this asymp-
tomatic population, no gadolinium 
chelate will be administered. Examples 
of MR images obtained with selected 
MR imaging sequences are provided in 
Figures 4–7.
Morphologic and functional imag-
ing of the brain.—Morphologic imaging 
212 radiology.rsna.org n Radiology: Volume 277: Number 1—October 2015
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Figure 4
Figure 4: MR images obtained as part of the neurologic MR imaging protocol. A, T1-weighted 3D 
magnetization-prepared rapid acquisition gradient-echo sequence. B, Two-dimensional fluid-attenuated 
inversion recovery sequence. C, Two-dimensional gradient-recalled-echo echo-planar imaging blood oxygen 
level–dependent sequence (for resting-state functional MR imaging).
will be performed by using (a) a T1-
weighted three-dimensional magneti-
zation-prepared rapid gradient-echo, 
or MPRAGE, sequence as a well-estab-
lished approach to volumetric and mor-
phometric analysis of regional brain 
structure (31) and (b) a predominantly 
T2-weighted fluid-attenuated inversion 
recovery sequence to detect white mat-
ter abnormalities mainly due to cardio-
vascular diseases (32). To characterize 
brain function, resting-state func-
tional MR imaging data will be ac-
quired by using a blood oxygen level–
dependent gradient-echo echo-planar 
imaging sequence, which will enable 
investigation of the functional organi-
zation of brain areas and their con-
nectivity in a task-free state (33,34). 
These parameters not only show rel-
evant changes during the process of 
aging (35) but also might be prom-
ising risk parameters with which to 
assess dementia and psychiatric and 
neurologic disorders (36,37).
Morphologic and functional imag-
ing of the cardiovascular system.—The 
cardiovascular MR protocol comprises 
Figure 5
Figure 5: Examples of MR images acquired as part of the cardiovascular protocol: A–C, Long-axis MR images 
obtained with the cine steady-state free precession sequence. D, Short-axis MR image obtained with cine steady-state 
free procession sequence. E, MR image obtained with T1 mapping (modified look-locker inversion recovery). F, Native 
thoracic MR angiogram.
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assessment of cardiac function, mor-
phologic native MR angiography of the 
thorax, and parametric T1 mapping 
to assess myocardial tissue. For left 
ventricular function and mass as the 
most investigated parameters for car-
diovascular outcomes, MR imaging is 
the established clinical reference stan-
dard (38). Reproducible standard long- 
and short-axis views of the heart will 
be acquired by using two-dimensional 
cine balanced steady-state free preces-
sion techniques (39). Steady-state free 
precession–based native angiography 
has been shown to be an alternative to 
contrast-based MR angiography (23) to 
cover the pulmonary arterial, venous, 
and aortic vasculature. Finally, the pro-
tocol will include parametric T1 map-
ping to detail myocardial tissue alter-
ations through changes in T1 (40).
Thoracoabdominal imaging.—MR 
imaging, especially T1-weighted two-
point Dixon techniques, enable reli-
able detection of fat and differentiation 
between adipose and lean tissue (41). 
Obese patients are at increased risk 
for many chronic diseases, including 
type-2 diabetes, cardiovascular disease, 
cancer, and osteoarthritis (42,43). Lo-
cal adipose tissue depots play a pivotal 
role in the pathogenesis of metabolic 
and atherosclerotic diseases; for exam-
ple, visceral fat is more important in 
the pathogenesis of insulin resistance 
than is subcutaneous fat because of its 
metabolic activity (44). Thus, quantifi-
cation of not only total adipose tissue, 
but more importantly quantification of 
local adipose tissue depots, such as vis-
ceral or epicardial fat, has the potential 
to be a novel risk marker for metabolic 
and cardiovascular disease (45). With 
a dedicated multiecho sequence (46), 
Figure 6
Figure 7
Figure 7: A, T2-weighted MR image of the thorax and abdomen obtained as part of the body protocol. B, C, MR 
images obtained as part of the musculoskeletal protocol (PD with fat saturation of the pelvis [B] and  
T2-weighted image of the entire spine [C] ).
Figure 6: Image examples as part of the thora-
coabdominal MR imaging protocol: A, T1-weighted 
3D volumetric interpolated breath-hold examination 
( VIBE) image from the neck to the knees with 
coronal reconstructed images. B, Body fat can 
be assessed with the two-point Dixon-technique 
separated fat images. C, D, Multiecho VIBE images 
with six echoes yield percentage-scaled fat (C) and 
R2
eff
 ( D) images of the liver.
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liver fat and iron content can be deter-
mined, which is an established prog-
nostic marker in hepatic disease. This 
sequence can also be used to identify 
pathophysiological links to diabetes 
and other metabolic diseases (12). T2-
weighted techniques enable imaging 
of free water and water content, such 
as in the process of inflammation or 
edema. Furthermore, it enables detec-
tion of chronic processes resulting in 
atrophy, cystic remodeling, or both as 
observed in the case of chronic pan-
creatitis, it improves visualization of 
dilated pancreatic or bile ducts and the 
decision between differential diagnosis 
of incidental findings (eg, between cys-
tic and solid lesions), and it improves 
accurate segmentation of the different 
tissue types. Finally, both techniques 
enable volumetric measurements of 
organs and defined normal volume 
ranges within a healthy population.
Musculoskeletal imaging.—Muscu-
loskeletal imaging will focus on the two 
major disease entities of osteoarthro-
sis (degenerative joint disease) and in-
flammatory joint disease. The protocol 
includes an established fat-suppressed 
1-mm isotropic spatial-resolution 3D 
fast spin-echo with variable flip angle 
contrast proton-density sequence of 
the pelvis to assess the most relevant 
phenotypic parameters of osteoarthro-
sis and inflammatory joint disease. In 
addition to cartilage and labrum condi-
tion, potential osteophytes or subcon-
dral cysts as markers of osteoarthrosis 
and femoroacetabular impingement 
can be assessed. Moreover, param-
eters for inflammatory joint disease, 
such as synovitis, joint effusion, articu-
lar bone marrow edema, and bursitis, 
will be imaged, and potential adjacent 
myopathies or tendinopathies can be 
visualized. Additionally, bone marrow 
lesions of the pelvic skeleton can be 
appreciated. Furthermore, the sacrum 
and the sacroiliac joints will be covered 
by the 3D fast spin-echo sequence so 
that signs of sacroiliitis will be de-
tected. In addition, a two-dimensional 
T2-weighted fast spin-echo sequence 
of the entire spine will enable visuali-
zation and assessment of disc degener-
ation and disc herniations (protrusion, 
extrusion, sequestration). Moreover, 
possible osteochondrosis, spondylo-
sis, osteoporosis with potential verte-
bral fractures, overall vertebral shape 
and potential endplate changes, spi-
nal canal stenosis, and bone marrow 
changes in the examined participants 
will be appreciated. The MR protocol 
for musculoskeletal imaging overlaps 
anatomically in part with the proto-
col for thoracoabdominal imaging and 
therefore can extend the research foci; 
an example is the 1-mm isotropic 3D 
fast spin-echo sequence in the pelvis, 
which allows precise volumetric mea-
surement of the prostate and its en-
largement (47).
Quality Assurance
One of the major challenges of popula-
tion-based imaging is to ensure high and 
identical image quality throughout the 
study period. In the MRI Study of the 
German National Cohort, a dedicated 
MR imaging core with different core 
units will serve as a central reference 
to address the challenges of quality as-
surance. All MR data acquired at each 
MR imaging center will be transferred 
to the central core, which in itself will 
provide long-term archived capacities.
The MR imaging core is designed 
as a distributed structure with a central 
coordination and training center (Mu-
nich, Germany), a dedicated MR data 
management center (Bremen, Germa-
ny), a quality assurance center (Greif-
swald, Germany), and a center for inci-
dental findings (Heidelberg, Germany). 
The four centers are connected via a 
Web-based digital image management 
system that allows for (a) communica-
tion, (b) evaluation and monitoring of 
enrollment progress and image quality, 
(c) certification and evaluation of train-
ing status or readers, and (d) quality 
assurance and monitoring of the man-
agement of incidental findings.
Coordination and Training Center
The coordination and training center 
ensures coordination of the overall ex-
ecution of the study, connects the im-
aging sites with the central MR imaging 
core, and ensures integration within 
the German National Cohort study. All 
study personnel will be centrally trained 
and certified in conducting fully stan-
dardized MR image acquisition and in 
on-site quality control. Respective ad-
herence to trained procedures and stan-
dard operating procedures (SOPs) will 
be monitored by those at the coordina-
tion and training center via regular site 
visits. Image interpretation training will 
be coordinated with the centers for inci-
dental findings and quality assurance in 
precisely defined tasks and closely inter-
linked roles, as will be described.
MR Data Management Center
The dedicated data management system 
provides the connection between the 
imaging sites, the imaging core centers, 
and the long-term data storage centers 
of the German National Cohort and the 
first steps of quality assurance. Basic au-
tomated quality assurance will include 
completeness of data, conformity of 
scan parameters and scan regions, and 
global image features that include sig-
nal-to-noise ratio and a universal image 
quality index (48). In detail, scores of 
program truth (complete MR examina-
tion) and protocol parameter truth (for 
each single MR protocol) are defined by 
cross comparison of each examination 
with a reference standard MR program 
covering a complete MR examination. 
Analysis of public and private Digital 
Imaging and Communications in Med-
icine header tags will enable extrac-
tion of order and timing information 
during the acquisition process and will 
reveal changes and deviations in rele-
vant MR parameters. Subsequently, 
image volumes are evaluated by using 
automatically generated background 
and foreground image masks that of-
fer position information, estimations of 
signal-to-noise ratio, image sharpness, 
structured noise, and N/2-ghosting level 
(49). The average assessment time for 
automated MR examination quality as-
surance is less than 60 minutes and is 
performed completely independent of 
the user and site.
The Web-based thin client tailored 
for the imaging program of the Ger-
man National Cohort will provide addi-
tional capabilities of quality assurance 
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(visual image quality rating) and inci-
dental finding readings at each of the 
MR imaging sites.
Center for Incidental Findings
This center is responsible for the man-
agement of incidental findings, which 
have been identified as a major chal-
lenge in population-based MR imaging 
(26,50–52). A particular challenge is 
attributed to the fact that the whole-
body unenhanced MR protocol is de-
signed for epidemiologic use with spe-
cific protocol parameters different from 
those used for clinical diagnostic imag-
ing. From this protocol, results are ob-
tained instead of diagnoses (eg, breast 
cancer cannot be observed with rea-
sonable specificity). Further difficulties 
are the unavailability of clinical history, 
clinical imaging results, or laboratory 
information. It is not known whether 
the “participant” is a “patient” with 
an already known finding or disease. 
On the basis of clinical guidelines, re-
cent research results, and ethical con-
siderations (50), the most commonly 
expected incidental findings have been 
listed and categorized by expert panels 
into three groups according to clinical 
relevance and urgency as “actionable,” 
“reportable,” and “nonreportable.”
Actionable results are those with 
a high likelihood to alter participants’ 
well-being within a short time and to 
require urgent medical treatment to 
prevent adverse outcome; examples are 
pneumothorax, acute stroke, or intra-
cranial hemorrhage. If these results are 
detected, the radiologist is required to 
get in direct contact with the partici-
pant and recommend immediate clini-
cal work-up at the next available emer-
gency department.
Reportable results are defined as 
follows: (a) the MR protocol allows high 
specificity for such a finding and (b) 
the finding has a reasonably high like-
lihood to alter participants’ well-being. 
Both conditions must be applicable for 
a reportable result. Examples are an 
aortic aneurysm with a diameter of 
more than 5 cm or an abdominal mass 
with a diameter of more than 3 cm. 
The participant will be informed of 
the detected results via a standardized 
letter within approximately 10 working 
days after the examination.
All other nonreportable results 
are incidental findings without known 
clinical relevance or a high false-pos-
itive rate that will not be disclosed to 
the participants. The list of nonre-
portable findings is exemplary (cystic 
renal lesions, fatty masses, etc) and 
serves as a guideline for the reader 
to categorize other findings that he or 
she might observe.
The center has also defined a 
process pathway for incidental findings 
that are currently not listed but may 
have clinical relevance, as indicated 
by the local radiologists. It includes a 
committee of radiologists, general prac-
titioners, epidemiologists, and ethicists 
who will determine whether a finding 
is actionable, reportable, or nonreport-
able based on the current clinical and 
scientific knowledge.
Together with the MR data manage-
ment center, the center for incidental 
findings has developed a tool to mark 
and report incidental findings within 
the Web-based thin-client viewer. The 
center will keep all reporting algorithms 
updated and will include clinical devel-
opments during the entire study period. 
It will serve as a contact for local radiol-
ogists´ inquiries in unclear cases.
To ensure the highest quality stan-
dards, the center will oversee all read-
ings, perform an overreading of a sub-
set of data sets regarding the incidental 
findings, and provide mandatory stan-
dardized training for all local incidental 
finding readers, who can be nominated 
by the local MR sites (eligible are med-
ical doctors who passed the National 
Board of Radiology examination and 
who are certified according to the in-
ternal quality assurance procedures). 
Reader certification involves personal 
on-site or Web-based training to ensure 
compliance with the SOPs. For certifi-
cation of local radiologists, whole-body 
MR images with available reference 
standards must be assessed by the po-
tential readers, and incidental findings 
must identified, marked, and reported 
in the same manner as during the study 
and according to SOPs. If the radiolo-
gists successfully pass the certification 
process, they will be granted access to 
the MR images via a personalized login. 
The access can be limited by study site, 
date, and login used.
The overreadings are performed 
by a senior radiologist from the cen-
ter for incidental findings. The first five 
cases are reevaluated for each newly 
certified local radiologist and the first 
20 cases for each newly activated MR 
site. In case of SOP deviations, direct 
contact is established to allow for cor-
rective measures and repeat training, 
if necessary. Additionally, during the 
course of the study, overreading will 
be performed in a subset of 10% of all 
cases per site using stratified random 
sampling with oversampling partici-
pants in whom incidental findings have 
been detected.
Quality Assurance Center
To address the challenge of multi-
center whole-body MR imaging, the 
quality assurance center will (a) mon-
itor reader certifications, (b) monitor 
mean prevalence of incidental findings 
per reader and per site over time, and 
(c) perform reevaluation of the MR 
cases in regard to image quality to en-
sure highest adherence to the SOPs. 
The reevaluation of MR cases in re-
gard to image quality is conducted in 
a random subset of 10% of all cases. 
Systematic deviations between sites, 
between individual readers, and/or 
over time are summarized and detect-
ed in comprehensive quality assurance 
reports, which provide comparative 
summaries of all previously outlined 
measures. Quality assurance reports 
are published quarterly throughout the 
entire data collection phase. The cen-
ter initiates corrective measures, such 
as retraining of technical or medical 
personnel.
Furthermore, the quality assurance 
center coordinates all local and cen-
tral procedures of quality assurance, 
such as the development and mainte-
nance of SOPs and local quality assur-
ance measures. This will be achieved 
in collaboration with the coordination 
and training center, which will develop 
procedures for and conduct site moni-
toring concerning SOP adherence in all 
Radiology: Volume 277: Number 1—October 2015 n radiology.rsna.org 217
SPECIAL REPORT: MR Imaging in the German National Cohort Bamberg et al
aspects of data acquisition. The quality 
assurance center is embedded into the 
quality management structure of the 
overall German National Cohort (25).
Summary
The MR Imaging Study of the German 
National Cohort will establish a large im-
age repository and will eventually yield 
comprehensive phenotypic information 
from a large European population. It can 
be anticipated that relevant new infor-
mation concerning the development of 
subclinical disease, overt disease states, 
and the relevance of findings on whole-
body MR images will be derived. The 
derived MR data will complement the 
clinical, biochemical, and genetic factors 
in major pathophysiologic domains and 
will be available to the national and in-
ternational scientific community.
To date, whole-body MR imaging 
has been used in smaller study cohorts 
and in the SHIP (Study of Health in 
Pomerania) project, a recently pub-
lished population-based study compris-
ing 3400 participants who underwent 
MR imaging in Germany (53). Imple-
mentation of larger MR imaging studies 
has been hampered by labor-intensive 
time-consuming acquisition techniques, 
which recently have changed greatly. 
However, it is still obvious that with 
limited imaging time available, applying 
whole-body imaging rather than organ-
specific imaging (eg, neurologic imag-
ing) represents a compromise between 
the achievable level of morphologic and 
functional details and a broad general 
coverage of the different body areas. 
In fact, this has resulted in the omis-
sion of many clinically and scientifically 
relevant pulse sequences (eg, vascular 
pulse sequences of the neurocranium or 
diffusion-tensor imaging). Also, with-
out the use of a gadolinium chelate as a 
contrast agent, the diagnostic accuracy 
of native imaging is particularly limited 
with respect to oncologic disease de-
tection and accurate assessment of the 
lungs, liver, pancreas, and kidneys.
In the setting of the German Na-
tional Cohort, with a general focus on 
population-based disease states, the 
applied whole-body imaging protocol 
may represent a balanced and suitable 
approach to population-based imaging, 
exploiting recent advances in MR im-
aging technology and covering major 
organ systems simultaneously. Similar 
approaches currently are being un-
dertaken in other large-scale cohort 
studies (54).
It is expected that the study results 
will be applicable to clinical practice 
through identification of novel imaging-
based biomarkers that enable us to 
best predict individual risk. To date, 
evidence on whole-body MR imag-
ing as a disease screening modality is 
limited and has been associated with 
overdiagnosis and risk of false-positive 
findings (55) while its clinical value in 
the diagnosis of systemic oncologic or 
inflammatory diseases is more estab-
lished (56). In the setting of such large 
studies, the obtained high-contrast im-
aging information will be primarily used 
to assess the prevalence of subclinical 
disease states and normal variants and 
to understand pathophysiologic path-
ways in the natural history of disease 
development, but it will also be used 
to identify novel imaging biomarkers of 
risk due to the longitudinal study de-
sign. If the results are positive, these 
data may form the scientific basis to 
justify dedicated research (ie, cost-ef-
fectiveness analysis) to establish whole-
body MR imaging in the setting of a 
broader risk assessment and screening. 
While particularly relevant to the po-
tential role of whole-body MR imaging 
in a future screening context, the man-
agement of incidental findings, which 
are expected to occur in up to one-third 
of participants, poses an immediate 
major challenge to the conduct of the 
study (51). On the one hand, imaging 
findings may result in identification of 
early and potentially treatable disease 
(50). On the other hand, a patient’s life 
could be affected by unnecessary work-
up, including a follow-up examination 
or invasive procedures in the case of 
false-positive findings. Either possibility 
could introduce scientific bias to the ini-
tial study objectives. Within this spec-
trum of ethical considerations, the MR 
imaging study of the German National 
Cohort will use standardized algorithms 
and reporting systems for the various 
incidental findings. Board-certified radi-
ologists will review all MR imaging data, 
and study participants will be notified 
if clinically relevant incidental findings 
are detected. However, as practicing 
clinicians know, there is a large cate-
gory of findings with low or unknown 
importance for the health of the partic-
ipants that will not be disclosed. While 
this approach is being closely followed 
by an expert panel, only the knowledge 
gained in the study will help redefine 
and optimize these management strat-
egies for incidental findings.
Although existing cohort studies 
including imaging components have re-
sulted in substantial advances in knowl-
edge and have helped establish novel 
markers of risk, they have been limited 
in their ability to enable detection of 
smaller effect modification between 
groups and associations because of the 
small sample size. Thus, the relatively 
large sample size of the multicenter 
design of the German National Cohort 
covering major areas of a large Europe-
an country will be particularly useful to 
elucidate smaller differences in the prev-
alence of subclinical disease between 
different regions and participants’ dis-
tinct sociodemographic characteristics, 
such as migration background, specific 
genetic predispositions, or both. How-
ever, despite the relatively large sample 
size and detectable small differences 
between groups (Fig 3), there is the re-
maining risk that observed differences 
may not be identified with statistical 
confidence, especially with respect to 
genetic associations. Thus, the study is 
similarly tailored to enable pooling of 
MR imaging data with other European 
and non-European cohorts to identify 
even small observable variations be-
tween subgroups of participants.
Notably, assessment of smaller dif-
ferences and variations requires one 
to take into account variability of ev-
ery MR imaging phenotype of interest. 
While this has been accomplished for 
more established techniques, such as 
measurement of coronary calcification 
(57), these measures of accuracy are 
very limited in the field of whole-body 
MR imaging due to recent development 
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of the technique, and dedicated re-
search will be necessary. However, ap-
plying identical MR imaging techniques 
and protocols throughout the imaging 
program of the German National Co-
hort will result in the lowest achievable 
variability.
In conclusion, population-based MR 
imaging as part of the German National 
Cohort represents not only a research 
opportunity to study the relationship be-
tween exposure and disease in a general 
European population with numerous sci-
entific ramifications but also a challenge 
with respect to quality assurance, data 
postprocessing, and management of in-
cidental findings. The implementation of 
identical MR imager technology and im-
aging protocols, as well as central imaging 
core structures, are critical to establish a 
comprehensive MR imaging data reposi-
tory that will serve as a valuable source 
to advance our current understanding of 
major disease states and will eventually 
result in more tailored imaging-driven 
disease prevention strategies. Large pro-
spective population-based cohort studies, 
such as the German National Cohort MR 
imaging study, are required to establish 
imaging-based biomarkers of risk.
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